Close Menu

NEW YORK – Day One Biopharmaceuticals, a company developing targeted cancer treatments for children, said on Wednesday it has raised $130 million in a Series B funding round led by RA Capital Management.

Other new investors that participated in the Series B round include Boxer Capital, BVF Partners, Franklin Templeton, Janus Henderson Investors, Perceptive Advisors, T. Rowe Price and Associates, and Viking Global Investors, along with existing investors Canaan, Access Biotechnology, and Atlas Venture.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.